extract: 2026-03-22-openevidence-sutter-health-epic-integration

Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -143,6 +143,12 @@ Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on
 
 US patent protection extends to 2031-2033 for Ozempic and Wegovy, creating a legal wall that prevents approved generic competition until then. The compounding pharmacy channel that provided affordable access during 2023-2025 closed in February 2025 when FDA removed semaglutide from the shortage list. This means the US will remain 'inflationary' through legal channels through 2031-2033, but gray market pressure from $15/month Indian generics versus $1,200/month Wegovy will create illegal importation at scale.
 
+### Additional Evidence (challenge)
+*Source: [[2026-03-22-health-canada-rejects-dr-reddys-semaglutide]] | Added: 2026-03-22*
+
+Health Canada rejected Dr. Reddy's generic semaglutide application in October 2025, delaying Canada launch to 2027 at earliest (8-12 month review cycle after resubmission). This contradicts the Session 9 projection of May 2026 Canada launch and reveals regulatory friction as a significant barrier to generic GLP-1 market entry. Canada's patents expired January 2026, but regulatory approval does not automatically follow patent expiration. The delay removes the primary high-income market data point for 2026, leaving only India's $15-55/month pricing as the sole confirmed generic market reference. Canada was expected to establish pricing floors for high-income markets with US-comparable health infrastructure, but that calibration point is now delayed 12+ months beyond patent cliff.
+
+
 
 
 Relevant Notes:

domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md

@@ -41,6 +41,12 @@ OpenEvidence reached 30M+ monthly consultations by March 2026, including a histo
 
 ARISE report reframes OpenEvidence adoption as shadow-IT workaround behavior rather than validation of clinical value. Clinicians use OE to 'bypass slow internal IT systems' because institutional tools are too slow for clinical workflows. This suggests rapid adoption reflects institutional system failure, not OE's clinical superiority.
 
+### Additional Evidence (extend)
+*Source: [[2026-03-22-openevidence-sutter-health-epic-integration]] | Added: 2026-03-22*
+
+Sutter Health (3.3M patients, ~12,000 physicians) integrated OpenEvidence into Epic EHR workflows in February 2026, marking the first major health-system-wide EHR embedding. This shifts OpenEvidence from standalone app to in-workflow clinical tool, institutionalizing what ARISE identified as physicians bypassing institutional IT governance.
+
+
 
 
 Relevant Notes:

domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md

@@ -33,6 +33,12 @@ OpenEvidence's 1M daily consultations (30M+/month) with 44% of physicians expres
 
 ---
 
+### Additional Evidence (extend)
+*Source: [[2026-03-22-openevidence-sutter-health-epic-integration]] | Added: 2026-03-22*
+
+The Sutter Health-OpenEvidence EHR integration creates a natural experiment in automation bias: the same tool (OpenEvidence) that was previously used as an external reference is now embedded in primary clinical workflows. Research on in-context vs. external AI shows in-workflow suggestions generate higher adherence, suggesting the integration will increase automation bias independent of model quality changes.
+
+
 Relevant Notes:
 - [[centaur team performance depends on role complementarity not mere human-AI combination]] -- the chess centaur model does NOT generalize to clinical medicine where physician overrides degrade AI performance
 - [[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]] -- the multi-hospital RCT found similar diagnostic accuracy with/without AI; the Stanford/Harvard study found AI alone dramatically superior

inbox/archive/health/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md

@@ -0,0 +1,53 @@
+---
+type: source
+title: "Health Canada Rejects Dr. Reddy's Generic Semaglutide Application — Canada Launch Delayed to 2027 at Earliest"
+author: "Business Standard / The Globe and Mail"
+url: https://www.business-standard.com/companies/news/dr-reddys-labs-semaglutide-generic-canada-approval-delay-125103001103_1.html
+date: 2025-10-30
+domain: health
+secondary_domains: []
+format: news article
+status: processed
+priority: high
+tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory, patent-cliff, obeda]
+---
+
+## Content
+
+**Business Standard (October 2025):** Dr. Reddy's timeline to launch generic injectable semaglutide in Canada was set to be disrupted after the firm received a non-compliance notice (NoN) from Canada's Pharmaceutical Drugs Directorate. The notice could delay the launch by at least 8-12 months.
+
+**The Globe and Mail (subsequent coverage):** Health Canada rejected Dr. Reddy's Laboratories' application to make generic semaglutide — a setback for what was poised to be one of the first generic competitors to Ozempic to hit the market in 2026.
+
+**Company response:** Dr. Reddy's stated it is "in constant touch with Canadian regulators" and has "sent replies to their queries." The Canada launch is "on pause."
+
+**India launch confirmed:** Separately, Dr. Reddy's launched "Obeda" (generic semaglutide for Type 2 diabetes) in India — this is confirmed from the March 21, 2026 India generic market launch (Session 9 findings).
+
+**Context:**
+- Canada's semaglutide patents expired January 2026
+- Dr. Reddy's was projecting May 2026 Canada launch in its 87-country rollout plan
+- Multiple legal/patent complications in Canada (Pearce IP analysis, patentlawyermagazine.com coverage on "semaglutide saga" in Canada)
+- Timeline: if re-submitted immediately after rejection, 8-12 months for new review = June-October 2026 re-submission → 2027 at earliest for approval
+
+**Session 9 error:** The March 21, 2026 research session projected Dr. Reddy's Canada May 2026 launch as a near-term confirmed data point. This was incorrect — the Health Canada rejection means no Canada data in 2026.
+
+## Agent Notes
+**Why this matters:** Canada was the single clearest near-term data point for what generic semaglutide looks like in a major, high-income market with a functioning generic drug approval system. India's Day-1 pricing ($15-55/month) established the floor for low-income markets. Canada would have established the floor for high-income markets with similar health infrastructure to the US. That data point is now delayed to 2027 at earliest.
+
+**What surprised me:** The Health Canada rejection was not anticipated in any of the bullish GLP-1 generic coverage. The India launch coverage (Sessions 8-9) projected smooth Canada entry given the January 2026 patent expiration. The regulatory rejection is a material setback to the "generic access within 12 months of patent expiry" narrative.
+
+**What I expected but didn't find:** An explanation of what specifically was non-compliant in Dr. Reddy's submission. The Business Standard coverage doesn't specify the technical grounds — whether it's manufacturing quality, bioequivalence data, device design, or another issue. This matters because different rejection reasons have different remediation timelines.
+
+**KB connections:**
+- Directly updates Session 9 finding (Canada May 2026 launch was a key thread — now confirmed delayed)
+- Recalibrates the GLP-1 global generic rollout timeline: India confirmed, Canada 2027+, Brazil/Turkey TBD
+- The "US gray market importation" thread (Sessions 8-9): Canada was expected to be the primary source of legal/gray market US importation. That channel is now delayed.
+- The GLP-1 KB claim update ("inflationary through 2035" → split by market): the Canada delay means international price data for high-income markets is further away than projected
+
+**Extraction hints:** The primary claim is a timeline correction: Canada generic semaglutide launch is 2027 at earliest (not 2026 as the global rollout narrative projected). The secondary claim is about regulatory friction as a barrier to generic market entry that the India-first narrative didn't adequately account for.
+
+**Context:** This source corrects a material error in Session 9. The May 2026 Canada launch was listed as a key active thread and near-term data point. That thread is now effectively closed until 2027. The India price data remains the only live data point for post-patent generic semaglutide markets.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: GLP-1 receptor agonists claim ("inflationary through 2035") and the Session 21 claim candidate about Dr. Reddy's 87-country rollout
+WHY ARCHIVED: Corrects the Session 9 projection; establishes regulatory friction as an underappreciated barrier to generic GLP-1 global rollout
+EXTRACTION HINT: The claim candidate from Session 9 about Dr. Reddy's clearing 87 countries for 2026 rollout needs updating — Canada is NOT in the 2026 timeline. The extractor should flag this as a correction to Session 9's claim candidate 2.

inbox/queue/.extraction-debug/2026-03-22-openevidence-sutter-health-epic-integration.json

@@ -0,0 +1,36 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "ehr-embedded-clinical-ai-increases-automation-bias-risk-compared-to-standalone-tools.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "health-system-procurement-bypasses-clinical-ai-safety-validation-when-tools-are-framed-as-information-not-diagnosis.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 6,
+    "rejected": 2,
+    "fixes_applied": [
+      "ehr-embedded-clinical-ai-increases-automation-bias-risk-compared-to-standalone-tools.md:set_created:2026-03-22",
+      "ehr-embedded-clinical-ai-increases-automation-bias-risk-compared-to-standalone-tools.md:stripped_wiki_link:human-in-the-loop clinical AI degrades to worse-than-AI-alon",
+      "ehr-embedded-clinical-ai-increases-automation-bias-risk-compared-to-standalone-tools.md:stripped_wiki_link:OpenEvidence became the fastest-adopted clinical technology ",
+      "health-system-procurement-bypasses-clinical-ai-safety-validation-when-tools-are-framed-as-information-not-diagnosis.md:set_created:2026-03-22",
+      "health-system-procurement-bypasses-clinical-ai-safety-validation-when-tools-are-framed-as-information-not-diagnosis.md:stripped_wiki_link:healthcare AI regulation needs blank-sheet redesign because ",
+      "health-system-procurement-bypasses-clinical-ai-safety-validation-when-tools-are-framed-as-information-not-diagnosis.md:stripped_wiki_link:OpenEvidence became the fastest-adopted clinical technology "
+    ],
+    "rejections": [
+      "ehr-embedded-clinical-ai-increases-automation-bias-risk-compared-to-standalone-tools.md:missing_attribution_extractor",
+      "health-system-procurement-bypasses-clinical-ai-safety-validation-when-tools-are-framed-as-information-not-diagnosis.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-22"
+}

inbox/queue/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md

@@ -7,9 +7,13 @@ date: 2025-10-30
 domain: health
 secondary_domains: []
 format: news article
-status: unprocessed
+status: enrichment
 priority: high
 tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory, patent-cliff, obeda]
+processed_by: vida
+processed_date: 2026-03-22
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -51,3 +55,13 @@ tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory,
 PRIMARY CONNECTION: GLP-1 receptor agonists claim ("inflationary through 2035") and the Session 21 claim candidate about Dr. Reddy's 87-country rollout
 WHY ARCHIVED: Corrects the Session 9 projection; establishes regulatory friction as an underappreciated barrier to generic GLP-1 global rollout
 EXTRACTION HINT: The claim candidate from Session 9 about Dr. Reddy's clearing 87 countries for 2026 rollout needs updating — Canada is NOT in the 2026 timeline. The extractor should flag this as a correction to Session 9's claim candidate 2.
+
+
+## Key Facts
+- Dr. Reddy's received a non-compliance notice (NoN) from Canada's Pharmaceutical Drugs Directorate in October 2025
+- Canada's semaglutide patents expired January 2026
+- Dr. Reddy's projected May 2026 Canada launch in its 87-country rollout plan
+- Regulatory re-submission and review timeline: 8-12 months minimum
+- Dr. Reddy's stated it is 'in constant touch with Canadian regulators' and has 'sent replies to their queries'
+- The Canada launch is 'on pause' per company statement
+- India launch of Obeda (generic semaglutide) confirmed March 21, 2026

inbox/queue/2026-03-22-openevidence-sutter-health-epic-integration.md

@@ -7,9 +7,13 @@ date: 2026-02-11
 domain: health
 secondary_domains: [ai-alignment]
 format: press release
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [openevidence, sutter-health, epic-ehr, clinical-ai, ehr-integration, workflow-ai, automation-bias, california]
+processed_by: vida
+processed_date: 2026-03-22
+enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -56,3 +60,12 @@ Announced February 11, 2026: Sutter Health (one of California's largest health s
 PRIMARY CONNECTION: Session 9 finding on OpenEvidence scale (30M+ monthly consultations, valuation-evidence asymmetry)
 WHY ARCHIVED: First major EHR integration of OE — changes the automation bias risk profile from standalone app to in-workflow embedded tool; no safety evaluation mentioned pre-deployment
 EXTRACTION HINT: Focus on the governance gap: EHR embedding without prospective safety validation. This is a structural claim about how health system procurement decisions interact with clinical AI safety evidence requirements.
+
+
+## Key Facts
+- Sutter Health operates 30 hospitals and 900+ care centers in California
+- Sutter Health has approximately 12,000 affiliated physicians
+- Sutter Health serves approximately 3.3 million patients annually
+- OpenEvidence-Sutter Health integration announced February 11, 2026
+- Integration enables natural-language search for guidelines, peer-reviewed studies, and clinical evidence within Epic EHR
+- Stated goal includes 'advance healthcare sustainability and medical AI safety'